Prevalence of Atrial Fibrillation and Reasons for Undertreatment with Oral Anticoagulants

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2023 Sep 13

PMID 37704908

Authors

Johan Lilja

Anders Sjalander

Sara Sjalander

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate the prevalence of atrial fibrillation (AF), the proportion of AF patients not receiving oral anticoagulation (OAC) and reasons for abstaining from OAC treatment.

Methods: A retrospective cross-sectional study of patients aged 18 years or older with an AF diagnosis on June 1st 2020 in Västernorrland County, Sweden. AF diagnosis was retrieved using the ICD10 code I.48, and medical records were reviewed for comorbidities and documented reasons to abstain OAC treatment.

Results: Of 197 274 residents in Västernorrland County, 4.7% (9 304/197 274) had a documented AF diagnosis. Of these, 19% (1 768/9 304) had no OAC treatment, including 4.2% (393/9 304) with no indication, 2.5% (233/9 304) with a questionable and 2.5% (231/9 304) with a documented clear contraindication for OAC. In total 9.8% (911/9 304) were not treated with OAC despite indication and no reasonable documented contraindication, thus 90.8% (8 447/9 304) of all AF-patients were eligible for OAC treatment. Common reasons for abstaining treatment without reasonable contraindication were present sinus rhythm in 13.7% (125/911), perceived not an OAC candidate in 10.6% (97/911) and anemia in the past in 4.3% (39/911).

Conclusions: In the population of Västernorrland County, a very high AF prevalence of 4.7% was found, of which just over 90% would theoretically benefit from OAC treatment. This is higher than previously reported and stresses the importance of stroke prevention in this large patient group.

References

Mas Dalmau G, Sant Arderiu E, Enfedaque Montes M, Sola I, Pequeno Saco S, Alonso Coello P . Patients' and physicians' perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. BMC Fam Pract. 2017; 18(1):3. PMC: 5234257. DOI: 10.1186/s12875-016-0574-0. View

Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M . Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J. 2006; 27(16):1954-64. DOI: 10.1093/eurheartj/ehl146. View

Friberg L, Bergfeldt L . Atrial fibrillation prevalence revisited. J Intern Med. 2013; 274(5):461-8. DOI: 10.1111/joim.12114. View

Bjorck F, Ek A, Johansson L, Sjalander A . Warfarin persistence among atrial fibrillation patients - why is treatment ended?. Cardiovasc Ther. 2016; 34(6):468-474. DOI: 10.1111/1755-5922.12224. View

Glazer N, Dublin S, Smith N, French B, Jackson L, Hrachovec J . Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007; 167(3):246-52. DOI: 10.1001/archinte.167.3.246. View

Pritchett R, Bem D, Turner G, Neil Thomas G, Clarke J, Fellows R . Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. Thromb Haemost. 2019; 119(2):294-307. DOI: 10.1055/s-0038-1676835. View

Rosenman M, Baker L, Jing Y, Makenbaeva D, Meissner B, Simon T . Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Curr Med Res Opin. 2012; 28(9):1407-14. DOI: 10.1185/03007995.2012.708653. View

Bungard T, Ghali W, Teo K, McAlister F, Tsuyuki R . Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med. 2000; 160(1):41-6. DOI: 10.1001/archinte.160.1.41. View

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

10.

Norberg J, Backstrom S, Jansson J, Johansson L . Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data. Clin Epidemiol. 2013; 5:475-81. PMC: 3862395. DOI: 10.2147/CLEP.S53420. View

11.

Ogilvie I, Newton N, Welner S, Cowell W, Lip G . Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010; 123(7):638-645.e4. DOI: 10.1016/j.amjmed.2009.11.025. View

12.

Hart R, Pearce L, Aguilar M . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-67. DOI: 10.7326/0003-4819-146-12-200706190-00007. View

13.

Connolly S, Eikelboom J, Joyner C, Diener H, Hart R, Golitsyn S . Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364(9):806-17. DOI: 10.1056/NEJMoa1007432. View

14.

Friberg L, Hammar N, Pettersson H, Rosenqvist M . Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J. 2007; 28(19):2346-53. DOI: 10.1093/eurheartj/ehm308. View

15.

Alamneh E, Chalmers L, Bereznicki L . Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?. Am J Cardiovasc Drugs. 2016; 16(3):183-200. DOI: 10.1007/s40256-016-0161-8. View

16.

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

17.

Nichol G, Lau A, Laupacis A . Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999; 159(7):677-85. DOI: 10.1001/archinte.159.7.677. View

18.

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View

19.

Wolf P, Abbott R, Kannel W . Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8):983-8. DOI: 10.1161/01.str.22.8.983. View

20.

Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2009; 137(2):263-72. DOI: 10.1378/chest.09-1584. View